Author:
Cheson Bruce D.,O’Brien Susan,Ewer Michael S.,Goncalves Marcus D.,Farooki Azeez,Lenz Georg,Yu Anthony,Fisher Richard I.,Zinzani Pierre L.,Dreyling Martin
Subject
Cancer Research,Oncology,Hematology
Reference24 articles.
1. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study;Casulo;J Clin Oncol,2015
2. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study;Kahl;Cancer,2010
3. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study;Cheson;J Clin Oncol,2018
4. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma;Witzig;J Clin Oncol,2003
5. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma;Gopal;N Engl J Med,2014
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献